Drug intelligence / Profile preview

H009

Development stage: Unknown
Lead developer: Nanjing Carephar Shenghui Pharmaceutical
Administration: Injection

Overview

H009 is an investigational drug administered via injection, currently undergoing a Phase II clinical study for the treatment of bleeding caused by acute gastric and duodenal ulcers of the upper digestive tract. It is also being developed for the assisted eradication of Helicobacter Pylori. The drug is being developed by Nanjing Carephar shenghui Pharmaceutical Co., Ltd.

Beyond the preview

Go deeper on H009.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on H009.

Explore the full profile